AzTrials
AzTrials

ERASERASGYNBS002NCT05738902

Adherence and Compliance to ERAS in Gynecological Surgery

An observational study of ERAS and Gynecologic Cancer, run by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of the study is to investigate the association between early non-compliance to ERAS in postoperative day 2 (POD2) with the rate of postoperative complications. Read more about this study

Who is it for?
Ages 18 to 75 years, women only
Conditions the study is for
ERAS, Gynecologic Cancer, Post Operative Pain
What is being tested?
Assessment of compliance to ERAS.
How many people
600 participants
Where
1 siteItaly
Study dates
30 May 2023to 31 Mar 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Study population: Women affected by hystological confirmed gynecological cancer treated with open access surgery.

Who may be able to join

  • histological diagnosis of primary or recurrent gynecological cancer (endometrial, uterine, tubo-ovarian and cervical cancer);
  • perioperative management according to ERAS guidelines;
  • age 18-75;
  • open access surgery.

Who cannot join

  • postoperative recovery in intensive care unit (planned or unplanned);
  • Covid19 positive status known at the moment of surgery;
  • minimally invasive access surgery or palliative surgery;
  • prior pelvic radiotherapy;
  • hyperthermic intraperitoneal chemotherapy;
  • previous abdominal surgery (excluding appendectomy and primary surgery for gynecological malignancy);
  • pelvic exenteration or lateral extended endopelvic resection (LEER).

Trial locations and contacts

1 site in 1 country.

Federico Ferrari, MD, PhD contact

00390303995341

federico.ferrari@unibs.it

Italy1 site, 1 recruiting
  • Federico Ferrari

    Brescia, BS, 25123

    Federico Ferrari, MD, PhD, 00390303995341, federico.ferrari@unibs.it

    Federico Ferrari, MD, PhD

    Recruiting

Other trials in Italy

About this study

Official title: Adherence and Compliance to ERAS in Gynecological Surgery as Predictor of Postoperative Complications

The aim of the study is to investigate the association between early non-compliance to ERAS in postoperative day 2 (POD2) with the rate of postoperative complications.

Read the detailed description

The aim of this prospective multicenter observational study is to investigate the association between the early non-compliance to ERAS in postoperative day 2 (POD2) with the rate of postoperative complications, in women undergoing open surgery for gynecological cancer.

Every POD is defined from 8.00 AM of the same day until 8.00 AM of the day after. Namely, POD0 is the day of surgery, while POD1 is the first day after surgery and so on.

According to the ERAS protocol the same day of surgery (POD0) the patients should be mobilized out of bed and allowed to take liquids by mouth at will. Removal of urinary catheter and starting of oral feeding is planned on POD1. Intravenous fluid infusion is stopped as early as possible according to oral feeding recovery at POD1.

POD2 is considered more adequated to measure the early ERAS compliance compared to POD1. In fact, according to previous published data in colonic surgery, a small delay in recovery within an ERAS pathway in POD1, can be the reflection of inadvertent intraoperative fluid overload, inadequate control pain and missing nausea and vomiting prophylasis. Moreover, late end time of surgery can further impair the full application of ERAS during POD1.

The compliance of the participants will be assessed in POD2 using the following 5 indicators derived from ERAS items.

  1. Poorly controlled pain with NRS>3, measured using a dedicated Patient Reported Outcomes form administered at 8 PM of POD2, covering the last 12 hours. The need of rescue dose of antalgic therapy does not affect the status of poorly controlled pain.
  2. Failure to remove urinary catheter, namely the manteinance of the catether after 8.00 AM of POD2.
  3. Administration of intravenous infusion as hydration therapy after 8.00 AM of POD2.
  4. Failure to have an adequate oral intake (namely refusal of having one or more of the proposed meals, producing hence a calories deficit).
  5. Poor mobilization, defined as less than 4 hours outside the bed during whole POD2.

Any postoperative complications will be recorded up to 30 days and classified according to Clavien Dindo classification. Complications graded as III or greater were considered as major.

STATISTICAL PLAN

According to the literature, the complication rate for gynecological surgery in the oncological field under the ERAS protocol is around 25%. A sample of 600 patients produces a 95% confidence interval ranging from 21.5% to 28.5%, with an estimate precision (semi-width of the confidence interval) equal to 3.5%.

Based on the five ERAS indicators of compliance as predictors (independent variables), the sample size is calculated using the generic rule of 10 events for each independent variable (15 variables), corresponding to 150 events. Considering the aforementioned complication rate (25%), the sample must be at least 600 patients. Reasoning on a single ERAS item represented in about 40% of the patients, a number of 600 guarantees to highlight an OR equal to 2.5 in a logistic model that considers other independent binary variables with a correlation of 0.7 between them.

The collected data will first be synthesized using the tools of descriptive statistics, with categorical variables synthesized through absolute and relative frequencies, and quantitative variables through mean ± standard deviation, or median and interquartile range. The complication rate will be summarized in terms of proportion (percentage) with relative 95% confidence interval calculated using the Clopper-Pearson estimator. The chi-square test, with Fisher's exact variant in the case of expected frequencies less than 5, will be used to evaluate the association between categorical variables and i) adherence to ERAS (in terms of the number of indicators considered) and ii) the primary outcome (complications). For normally distributed quantitative variables the ANOVA test will be used; in the absence of the normality assumption underlying the test, the Kruskal-Wallis non-parametric test will be employed. Appropriate post-hoc comparisons, taking into account test multiplicity (multiples), will be conducted to identify ERAS item "pairs" that show statistical significance with the primary outcome.

The logistic regression model will be used to quantify the association and magnitude between the five ERAS indicators considered individually and the primary outcome represented by the presence of postoperative complications. An ordinal variable will also be constructed, with values from 1 to 5, which summarizes adherence to the five ERAS indicators. The magnitude of the association between the five ERAS indicators will first be quantified in terms of Odds Ratio (OR) and related confidence interval in a univariate setting, and then in a multivariate model that will consider the above adjustment variables. In the construction of the multivariate model, methods for choosing the predictors will be taken into consideration, such as the backward (and/or stepwise) technique. The results of the regression model will also be graphically represented through the "confidence-interval plot", a graphical representation that summarizes the punctual estimate of the OR and its 95% confidence interval. All analyzes will be performed considering a type I error α equal to 5%.

Being tested
Assessment of compliance to ERAS.
Keywords
ERAS; gynecologic cancer;
Medical subject headings
Pain, Postoperative, Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Assessment of compliance to ERAS.Other

    Assessment of compliance to ERAS in postoperative day 2 (POD2) using five indicators based on ERAS items and association with postoperative complications up to 30 days after discharge.

Study groups in NCT05738902
Study groupRoleWhat they receive
Women affected by gynecological cancer.Women affected by confirmed gynecological cancer treated with open access surgery and managed according to ERAS guidelines.
Receives: Other: Assessment of compliance to ERAS.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Early non-compliance to ERAS

    Association between the early non-compliance to ERAS with the rate of postoperative complications.

    Measured: Postoperative day 2 (POD2)

Secondary outcomes (1)
  1. Early non-compliance to ERAS in tubo-ovarian cancer

    Subgroup analysis association between the early non-compliance to ERAS with the rate of postoperative complications in women undergoing surgery for tubo-ovarian cancer

    Measured: Postoperative day 2 (POD2)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Feb 2023
  2. Study start30 May 2023
  3. Primary completion31 Mar 2025 (estimated)
  4. Study completion31 Mar 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05738902
Sponsor's protocol ID
ERASGYNBS002
Acronym
ERASGYNBS002
Status last verified
Jan 2024
First submitted
13 Feb 2023
Last updated
25 Jan 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Ferrari F, Bizzarri N, Fagotti A, Scambia G, Gozzini E, Soleymani Majd H, Rota M, Odicino F. Early non-compliance to ERAS in gynecological open surgery for malignancies, and post-operative complications: a multicenter, prospective, observational, cohort study. Int J Gynecol Cancer. 2025 Dec;35(12):101833. doi: 10.1136/ijgc-2024-005648. Epub 2025 Apr 17.

    PubMed 39379327

Questions about this trial

What is this clinical trial studying?

An observational study of ERAS and Gynecologic Cancer, run by Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Federico Ferrari, MD, PhD (00390303995341, federico.ferrari@unibs.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Early non-compliance to ERAS (time frame: Postoperative day 2 (POD2)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05738902, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in